Is Artrya's (ASX:AYA) US Salix Push Redefining Its AI Cardiac Imaging Investment Narrative?

Simply Wall St.

Jun 23

Artrya has recently attracted increased investor attention for its Salix platform, which uses artificial intelligence to analyse cardiac CT scans and help detect coronary artery disease, supported by ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2645885689"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2645885689\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2645885689?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574","is_english":true,"pubTime":"2026-06-23 13:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645885689","market":"us","top_or_hot":-1,"title":"Is Artrya's (ASX:AYA) US Salix Push Redefining Its AI Cardiac Imaging Investment Narrative?","media":"Simply Wall St.","content":"<div>\n<p>Artrya has recently attracted increased investor attention for its Salix platform, which uses artificial intelligence to analyse cardiac CT scans and help detect coronary artery disease, supported by ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/healthcare/asx-aya/artrya-shares/news/is-artryas-asxaya-us-salix-push-redefining-its-ai-cardiac-im\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Artrya's (ASX:AYA) US Salix Push Redefining Its AI Cardiac Imaging Investment Narrative?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Artrya's (ASX:AYA) US Salix Push Redefining Its AI Cardiac Imaging Investment Narrative?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-23 13:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/healthcare/asx-aya/artrya-shares/news/is-artryas-asxaya-us-salix-push-redefining-its-ai-cardiac-im><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Artrya has recently attracted increased investor attention for its Salix platform, which uses artificial intelligence to analyse cardiac CT scans and help detect coronary artery disease, supported by ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/healthcare/asx-aya/artrya-shares/news/is-artryas-asxaya-us-salix-push-redefining-its-ai-cardiac-im\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4210","symbol_name":"白银","start_time":0,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-aya/artrya-shares/news/is-artryas-asxaya-us-salix-push-redefining-its-ai-cardiac-im","article_id":"2645885689","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-aya/artrya-shares/news/is-artryas-asxaya-us-salix-push-redefining-its-ai-cardiac-im","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2645885689","pubTimestamp":1782192296,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Artrya has recently attracted increased investor attention for its Salix platform, which uses artificial intelligence to analyse cardiac CT scans and help detect coronary artery disease, supported by ongoing work on clinical validation, regulatory clearances and US market entry.\nAn interesting aspect of this development is how the push to convert early clinical evidence and regulatory progress into meaningful healthcare provider adoption will test Artrya’s commercialisation model for...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4210":"白银","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","AYA.AU":"ARTRYA LTD","AYA":"Aya Gold & Silver Inc","AGIX":"通用人工智能 ETF-AGIX","BK7094":"医疗保健技术","ARTY":"ISHARES FUTURE AI & TECH ETF","AIPO":"Defiance AI and Power Infrastructure ETF"},"translate_title":"Artrya(ASX：AYA)推动美国Salix是否正在重新定义其人工智能心脏成像投资叙事？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AYA.AU":1.5,"AGIX":1.5,"AIPO":1.5,"AYA":1.5,"CHAT":1.5,"ARTY":1.5},"content_text":"Artrya has recently attracted increased investor attention for its Salix platform, which uses artificial intelligence to analyse cardiac CT scans and help detect coronary artery disease, supported by ongoing work on clinical validation, regulatory clearances and US market entry. An interesting aspect of this development is how the push to convert early clinical evidence and regulatory progress into meaningful healthcare provider adoption will test Artrya’s commercialisation model for AI-driven cardiac imaging. We’ll now examine how Artrya’s focus on US regulatory progress and provider adoption for Salix affects the company’s existing investment narrative. We've uncovered the 6 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.AdvertisementArtrya Investment Narrative RecapTo own Artrya, you need to believe its Salix platform can turn clinical validation and US regulatory progress into sustained scan volumes and revenue, before cash outflows and losses become a concern. The latest attention on Salix reinforces that the key short term catalyst remains US provider adoption, while the biggest current risk is that revenue continues to lag elevated operating spend and SAPPHIRE-related investment. Overall, this news does not materially change those priorities. The FDA 510(k) clearances for Salix Coronary Anatomy and, more recently, the Salix Coronary Plaque module are the announcements most aligned with this news flow, because they set the foundation for broader US rollout at reimbursement levels the company has already outlined. These clearances help frame how Salix could participate in growing CCTA volumes and existing plaque assessment reimbursement, but they only translate into outcomes for shareholders if hospitals actually integrate the software at scale and maintain usage. Yet for all the progress on Salix, investors should be aware that... Read the full narrative on Artrya (it's free!)Artrya's narrative projects A$73.8 million revenue and A$32.3 million earnings by 2029. This requires 251.0% yearly revenue growth and a A$52.0 million earnings increase from A$-19.7 million today.Uncover how Artrya's forecasts yield a A$6.62 fair value, a 28% upside to its current price.Exploring Other PerspectivesASX:AYA 1-Year Stock Price Chart Six fair value estimates from the Simply Wall St Community span roughly A$0.00 to A$37.00 per share, highlighting very different expectations. You can weigh these views against the central catalyst of US Salix adoption and consider what that might mean for Artrya’s ability to close the gap between minimal revenue and ongoing cash burn.Explore 6 other fair value estimates on Artrya - why the stock might be worth over 7x more than the current price!Form Your Own VerdictDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Artrya research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.Our free Artrya research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Artrya's overall financial health at a glance.Ready To Venture Into Other Investment Styles?Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:AI is about to change healthcare. These 10 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.The latest GPUs need a type of rare earth metal called Terbium and there are only 30 companies in the world exploring or producing it. Find the list for free.Uncover the next big thing with 58 elite penny stocks that balance risk and reward.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}